What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Orforglipron, Placebo for obesity, overweight.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening: * hypertension * dyslipidemia * obstructive sleep apnea, or * cardiovascular disease * Have a history of at least one unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have an unstable body weight within 90 days prior to screening * Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening * Have acute or chronic hepatitis or pancreatitis * Are taking other medications or alternative remedies to manage weight loss
Study sites by state
Arizona
- Clinical Research Institute of Arizona (CRI) - Sun City West — Sun City West
- Novak Clinical Research - Tucson - North La Cholla Boulevard — Tucson
California
- Norcal Endocrinology & Internal Medicine — San Ramon
- Southern California Clinical Research — Santa Ana
- Care Access - Thousand Oaks — Thousand Oaks
Florida
- Accel Research Sites - DeLand Clinical Research Unit — DeLand
- Innovation Medical Research Center - Fort Lauderdale — Fort Lauderdale
- Indago Research & Health Center, Inc — Hialeah
- Encore Medical Research — Hollywood
- West Orange Endocrinology P.A. — Ocoee
- Care Access - Tampa — Tampa
- Conquest Research — Winter Park
Georgia
- Accel Research Sites - NeuroStudies Clinical Research Unit — Decatur
- Care Access - Decatur — Decatur
- Javara - Privia Medical Group Georgia - Savannah — Savannah
- North Georgia Clinical Research — Woodstock
Idaho
- Solaris Clinical Research — Meridian
Louisiana
- Care Access - New Iberia — New Iberia
Maryland
- Endocrine and Metabolic Consultants — Rockville
- Javara - Privia Medical Group - Silver Spring — Silver Spring
Michigan
- Great Lakes Research Group, Inc. — Bay City
Montana
- Boeson Research MSO — Missoula
Nevada
- Javara - Nevada Health Centers - Carson City — Carson City
- The Machuca Foundation — Las Vegas
North Carolina
- University of North Carolina Medical Center — Chapel Hill
- Javara - Tryon Medical Partners — Charlotte
- Care Access - Fayetteville — Fayetteville
Oregon
- The Corvallis Clinic, P.C. — Corvallis
Pennsylvania
- Clinical Research of Philadelphia — Philadelphia
- Frontier Clinical Research, LLC — Smithfield
Texas
- Velocity Clinical Research, Dallas — Dallas
- Biopharma Informatic, LLC — Houston
- Activian Clinical Research — Kingwood
- Texas Valley Clinical Research (TVCR) - Mission — Mission
- Consano Clinical Research, LLC — Shavano Park
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)